Consano Bio Presents Favorable Nonclinical Safety Results for C-1101 at the American College of Toxicology 46th Annual Meeting

BURLINGTON, MA — November 21, 2025 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced positive data from its nonclinical safety and toxicology program for C-1101, supporting initiation of a Phase 1 clinical trial in patients with chronic painful lumbosacral radiculopathy (LSR), or chronic sciatica. The results were presented in a poster at the American College of Toxicology (ACT) 46th Annual Meeting in Phoenix, AZ. READ MORE